



Statin Therapy for Patients with Cardiovascular Disease

Male patients ages 21-75 and female patients ages 40-75 identified as having ASCVD should be prescribed a moderate to high-intensity statin within the measurement year. Only one pharmacy fill is needed to close the gap.

Documentation of "statin intolerance" alone will not exclude the patient from the measure.

Exclusions:

- Pregnancy or IVF
- ESRD
- Cirrhosis
- Myopathy, myalgia, myositis, or rhabdomyolysis
- Hospice or palliative care
- > 66 years of age with advanced illness and frailty diagnoses

Description	Prescription
High-intensity statin therapy	Atorvastatin 40-80 mg
High-intensity statin therapy	Amlodipine-atorvastatin 40-80 mg
High-intensity statin therapy	Rosuvastatin 20-40 mg
High-intensity statin therapy	Simvastatin 80 mg
High-intensity statin therapy	Ezetimibe-simvastatin 80 mg
Moderate-intensity statin therapy	Atorvastatin 10-20 mg
Moderate-intensity statin therapy	Amlodipine-atorvastatin 10-20 mg
Moderate-intensity statin therapy	Rosuvastatin 5-10 mg
Moderate-intensity statin therapy	Simvastatin 20-40 mg
Moderate-intensity statin therapy	Ezetimibe-simvastatin 20-40 mg
Moderate-intensity statin therapy	Pravastatin 40-80 mg
Moderate-intensity statin therapy	Lovastatin 40 mg
Moderate-intensity statin therapy	Fluvastatin 40-80 mg
Moderate-intensity statin therapy	<u>Pitavastatin 1-4 mg</u>

Diagnoses that will exclude the patient from the measure must be assessed and submitted to the insurance company annually.